|Stock:||Warner Chilcott Plc|
|Warner Chilcott Public Limited Company is a specialty pharmaceutical company. It is focused on the women’s healthcare, gastroenterology, dermatology and urology segments of the branded pharmaceuticals market, primarily in North America. It is an integrated company with internal resources focused on the development, manufacture and promotion of its products. Its women’s healthcare franchise is anchored by its presence in the hormonal contraceptive, osteoporosis and hormone therapy (HT) markets. The Company’s hormonal contraceptive product offerings include LOESTRIN 24 FE (norethindrone acetate and ethinyl estradiol tablets, USP and ferrous fumarate tablets), the branded product in the United States hormonal contraception market, and LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol tablets, ethinyl estradiol tablets and ferrous fumarate tablets), its new oral contraceptive product that offers women the lowest dosage of estrogen of any oral contraceptive.|
Copyright © 2013 Microsoft. All rights reserved.
Quotes are real-time for NASDAQ, NYSE and AMEX. See delay times for other exchanges.
Fundamental company data and historical chart data provided by Thomson Reuters (click for restrictions). Real-time quotes provided by BATS Exchange. Real-time index quotes and delayed quotes supplied by Interactive Data Real-Time Services. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations data provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by SIX Financial Information.